(MedPage Today) — Maintenance therapy with continuous lenalidomide (Revlimid) did not significantly improve overall survival (OS) in patients with standard-risk, newly diagnosed multiple myeloma, the phase III ENDURANCE trial showed.
Among patients…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
